Showing results (241-250 of 288) with videos related to

Sort By:
Pageof 29
Cytokine|January 9, 2001
BLyS BINDS TO B CELLS WITH HIGH AFFINITY AND INDUCES ACTIVATION OF THE TRANSCRIPTION FACTORS NF-kappaB AND ELF-1P Kanakaraj, T S Migone, B Nardelli, et al.
Blood|January 3, 2001
Synthesis and release of B-lymphocyte stimulator from myeloid cellsB Nardelli, O Belvedere, V Roschke, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 9, 2002
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseasesViktor Roschke, Svetlana Sosnovtseva, Christopher D Ward, et al.
European Journal of Internal Medicine|April 14, 2018
Clinical outcomes of Clostridium difficile infection according to strain type. A prospective study in medical wardsS Serafino, D Consonni, M Migone De Amicis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2009
A novel family with Lamin B1 duplication associated with adult-onset leucoencephalopathyA Brussino, G Vaula, C Cagnoli, et al.
Transplant Immunology|September 10, 2021
BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitizationDivyansh Agarwal, Eline T Luning Prak, Tina Bharani, et al.
Transboundary and Emerging Diseases|November 1, 2022
A search for piroplasmids and spirochetes in threatened pudu (Pudu puda) and associated ticks from Southern Chile unveils a novel Babesia sp. and a variant of Borrelia chilensisAdriana Santodomingo, Sofía Robbiano, Richard Thomas, et al.
Human Mutation|December 5, 2019
Comparison of the functional and structural characteristics of rare TSC2 variants with clinical and genetic findingsLuiz G Dufner Almeida, Santoesha Nanhoe, Andrea Zonta, et al.
Plos One|October 12, 2012
Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivoTroy A Luster, Ipsita Mukherjee, Jeffrey A Carrell, et al.
Vaccine|July 18, 2024
A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and olderJ Wassil, M Sisti, J Fairman, et al.
Pageof 29